CorMedix Inc
CRMD16.560USD
+2.950+21.68%
收盘 06/23, 16:00（美东）报价延迟15分钟
1.12B总市值
亏损市盈率 TTM
关于 CorMedix Inc 公司
CorMedix Inc. 是一家生物制药公司。该公司专注于开发和商业化用于预防和治疗危及生命的病症和疾病的治疗产品。该公司专注于商业化其主打产品 DefenCath，这是一种抗菌导管锁定溶液，经批准用于降低通过中央静脉导管接受慢性血液透析的肾衰竭成年患者的导管相关血流感染发生率。DefenCath 是一种由 13.5 mg/mL 牛磺罗定和 1000 USP 单位/mL 肝素组成的配方，用于降低通过中央静脉导管 (CVC) 接受慢性血液透析的肾衰竭成年患者的导管相关血流感染 (CRBSI) 发生率。除了 DefenCath 之外，该公司还赞助了一项临床前研究合作，以研究牛磺罗定作为罕见儿科肿瘤的潜在治疗方法。
公司简介
公司代码CRMD
公司名称CorMedix Inc
上市日期Mar 25, 2010
成立日期2006
CEOMr. Joseph Todisco
员工数量64
证券类型Ordinary Share
年结日Mar 25
公司地址300 Connell Drive
城市BERKELEY HEIGHTS
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编07922
电话19085179500
网址https://cormedix.com/
公司代码CRMD
上市日期Mar 25, 2010
成立日期2006
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
收入明细
FY2024
暂无数据
地区USD
名称
营收
占比
United States
43.47M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
股东类型
持股股东
占比
Investment Advisor
13.86%
Investment Advisor/Hedge Fund
13.60%
Hedge Fund
5.69%
Research Firm
1.60%
Sovereign Wealth Fund
1.39%
Individual Investor
1.19%
Pension Fund
0.45%
Bank and Trust
0.30%
Venture Capital
0.06%
Other
61.88%
机构持股
更新时间: 2月24日 周一
更新时间: 2月24日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
262
29.51M
43.73%
+3.54M
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
2022Q4
191
11.93M
28.90%
-1.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
4.20M
6.44%
+868.26K
+26.06%
Dec 31, 2024
The Vanguard Group, Inc.
3.38M
5.18%
+309.51K
+10.09%
Dec 31, 2024
Elliott Management Corporation
2.87M
4.4%
+1.32M
+85.14%
Dec 31, 2024
State Street Global Advisors (US)
1.45M
2.23%
+227.39K
+18.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.39M
2.14%
+108.36K
+8.44%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
940.59K
1.44%
+940.59K
--
Dec 31, 2024
UBS Financial Services, Inc.
379.87K
0.58%
+340.35K
+861.30%
Dec 31, 2024
Morgan Stanley & Co. LLC
283.12K
0.43%
+50.06K
+21.48%
Dec 31, 2024
Northern Trust Investments, Inc.
510.89K
0.78%
+100.11K
+24.37%
Dec 31, 2024
查看更多
持股ETF
更新时间: 6月6日 周五
更新时间: 6月6日 周五
机构名称
占比
SPDR S&P Pharmaceuticals ETF
1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Active Factor Small Cap ETF
0.17%
iShares Micro-Cap ETF
0.13%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
查看更多
SPDR S&P Pharmaceuticals ETF
占比1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
占比0.49%
First Trust Active Factor Small Cap ETF
占比0.17%
iShares Micro-Cap ETF
占比0.13%
Vanguard US Momentum Factor ETF
占比0.1%
Invesco Nasdaq Biotechnology ETF
占比0.08%
iShares Biotechnology ETF
占比0.07%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
